Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results of ATG-008 (mTORC1/2 inhibitor) and preclinical data of ATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (LILRB4 antagonist antibody) SHANGHAI and HONG KONG, March 20, 2023 /PRNewswire/ -- Antengene Corporation...
Innovating for better sleep
BEIJING, March 20, 2023 /PRNewswire/ -- Sleep is essential for health. Like eating well and exercising, sleep is a behavior that is essential to a person's physical, mental, and social well-being. However, sleep is not yet universally recognized as an essential behavior for physical health.1 BMC Medical Co., Ltd. has been dedicated to sleep and respiratory health for more...
320 World Oral Health Day – Lifting the “mask mandate”, maintaining good oral hygiene and flashing a healthy and confident smile.
HONG KONG, March 20, 2023 /PRNewswire/ -- According to a report released by the World Health Organization (WHO) in 2022, oral diseases are the most common non-communicable diseases in humans and affect 3.5 billion people worldwide. Approximately 2 billion people have untreated caries in permanent teeth and 514 million children have untreated caries in deciduous teeth. In response to "World...
AffaMed Technologies Announces TFDA Approval of MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready IOLs for Cataract Treatment in Taiwan
SHANGHAI, March 20, 2023 /PRNewswire/ -- AffaMed Technologies, a joint venture established between AffaMed Therapeutics and SIFI S.p.A., today announced that the Taiwan Food and Drug Administration ("TFDA") has approved its MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready intraocular lens ("IOL") surgical implants for use in cataract treatment in Taiwan. MINI WELL, MINI...
Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting
At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33% achieving HiSCR100. Safety results were consistent with previous trials of izokibep and the IL-17Ai class, with no increased risk of infection, including candida. SAN DIEGO, SHANGHAI and SYDNEY, March 20, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the topline 12-week data...
AMGEN AND NSG BIOLABS ANNOUNCE ALBATROZ THERAPEUTICS AS WINNER OF FIRST AMGEN GOLDEN TICKET IN SINGAPORE
The Golden Ticket will help to boost the biotech startup's capabilities and to develop further the emerging biotech ecosystem in Southeast Asia SINGAPORE, March 20, 2023 /PRNewswire/ -- Leading global biotechnology company Amgen and NSG BioLabs, Singapore's largest and leading provider of biotechnology (biotech) co-working laboratories and offices, announced Albatroz Therapeutics as...
FDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health
Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population GENEVA, March 20, 2023 /PRNewswire/ -- - Picture is available at AP Images (http://www.apimages.com) - Today, FDI World Dental Federation (FDI) called on governments and global health bodies to prioritise action against oral diseases, including through integrating oral health at...
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
CHENGDU, China, March 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and accelerate its commercialization progress in 2022. Development of Innovative and Differentiated Pipelines Core Product CM310 (IL-4Rα antibody): Initiated Phase III...
Hanmi Pharmaceutical’s Combination Drug for Dyslipidemia Treatment, ‘Rosuzet’: Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in ‘The Lancet’ & ‘European Heart Journal’
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pharmaceutical company, Hanmi Pharmaceutical's Rosuzet is a dyslipidemia medicine, is a single-pill...
RVAC Medicines announces research collaboration with University of Pennsylvania mRNA Vaccine Pioneer
BOSTON, March 17, 2023 /PRNewswire/ -- RVAC Medicines (US), Inc., a messenger RNA (mRNA) technology company with its global headquarters in Singapore, today announced the collaboration under a Sponsored Research Agreement with the University of Pennsylvania ("Penn") focused on the discovery and development of mRNA vaccines that can modulate the body's normal immune response as possible treatments for certain...
